3 completed, 3 recruiting, 3 terminated, 2 not yet recruiting. 5 Phase 1, 3 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Recruiting 2, Completed 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 3 | Completed 1, Terminated 1, Withdrawn 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
Follow Solid Tumor Malignancy: new trials by email Literature Review of Solid Tumor Malignancy trials Research Report on Solid Tumor Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients 68Ga-FAPI-46 - Solid Tumor Cancer, Solid Tumor Malignancy | Early Phase 1 | Withdrawn | Eben Rosenthal | 2027-01-01 | 2026-01-21 | |
| Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes Ataraxis testing - Solid Tumor Malignancy, Breast Cancer | Not yet recruiting | Ataraxis AI, Inc. | 1000 | 2026-10-31 | 2026-10-06 | |
| Safety Trial of 68Ga/177Lu-NRT6020 in FAP-Positive Advanced Solid Tumor Patients 68Ga-NRT6020 Injection, 177Lu-NRT6020 Injection (stage 2), 177Lu-NRT6020 Injection (stage 3) - Solid Tumor Malignancy | Phase 1 | Recruiting | Chengdu New Radiomedicine Technology Co. LTD. | 132 | 2025-11-29 | 2026-02-02 |
| A Clinical Trial of SIBP-A18 Injection in the Treatment of Advanced Malignant Solid Tumor Patients SIBP-A18 - Solid Tumor Malignancy | Phase 1 | Recruiting | Shanghai Institute Of Biological Products | 156 | 2025-06-16 | 2026-01-07 |
| Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor: a Prospective Exploratory Study 99mTc-FDPH46 SPECT/CT Imaging - Malignant Tumors, Solid Tumor Malignancy | Not yet recruiting | Zhejiang University | 20 | 2024-12-28 | 2024-12-31 | |
| A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors XL495, ADC cytotoxic agents - Solid Cancers, Solid Tumor Cancer | Phase 1 | Terminated | Exelixis | 9 | 2024-10-17 | 2025-06-25 |
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product No Intervention - Hematological Malignancy, Solid Tumor Malignancy | Recruiting | Century Therapeutics, Inc. | 375 | 2024-04-29 | 2025-06-25 | |
| HLA-A*02:01 Allele Frequency and the NY-ESO-1 Expression Status in Cancer Patients in Taiwan Solid Tumor Malignancy | Terminated | PharmaEssentia | 485 | 2023-03-14 | 2026-07-22 | |
| Evaluating Immune Response to COVID-19 Vaccines in Patients With Cancer, Transplant or Cellular Therapy Recipients Cancer, Hematopoietic System--Cancer | Completed | St. Jude Children's Research Hospital | 21 | 2022-06-29 | 2026-04-15 | |
| A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy Messenger ribonucleic acid (mRNA)-1273 Vaccine, Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster, ECG - Solid Tumor Malignancy, Hematologic Malignancy | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2021-04-28 | 2024-08-27 |
| Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Pemigatinib - Solid Tumor Malignancy | Phase 2 | Terminated | Incyte Corporation | 111 | 2019-10-17 | 2025-11-04 |
| Selinexor Combination Ph 1 Study Selinexor, Irinotecan - Solid Tumor Malignancy | Phase 1 / Phase 2 | Withdrawn | Martin Gutierrez | 2014-09-01 | 2022-01-04 | |
| Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas SNX-5422 Mesylate Hsp90 inhibitor - Solid Tumor Malignancy, Lymphoid Malignancy (Lymphoma and CLL) | Phase 1 | Completed | Esanex Inc. | 32 | 2008-03-01 | 2012-05-17 |
Neoplasms (4) · Hematologic Neoplasms (3) · Leukemia (2) · Lymphoma (2) · Acrocephalosyndactylia (1) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Multiple Myeloma (1) · Neoplasm Metastasis (1)
Neoplasms by Site (5) · Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (3) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Adenocarcinoma (1) · Blood Protein Disorders (1) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Breast Diseases (1) · Carcinoma (1)
2019-nCoV Vaccine mRNA-1273 (1) · Anti-Bacterial Agents (1) · Antiemetics (1) · Antifungal Agents (1) · Electrocardiography (1) · FAPI-46 (1) · Irinotecan (1) · RNA, Messenger (1) · pemigatinib (1) · selinexor (1)
Ataraxis AI, Inc. (1) · Century Therapeutics, Inc. (1) · Chengdu New Radiomedicine Technology Co. LTD. (1) · Eben Rosenthal (1) · Esanex Inc. (1) · Exelixis (1) · Incyte Corporation (1) · Martin Gutierrez (1) · National Cancer Institute (NCI) (1) · PharmaEssentia (1) · Shanghai Institute Of Biological Products (1) · St. Jude Children's Research Hospital (1) · Zhejiang University (1)
United States (8) · China (3) · Denmark (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · South Korea (1) · Spain (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Diego Hijano, MD (1) · Eben Rosenthal, MD (1) · James Gulley, M.D. (1) · Jan Witowski, MD, PhD (1) · Jing Huang, Docter (1) · Peter Langmuir, MD (1)
PMID 32169911, PMID 34904839, PMID 35011496, PMID 36477400, PMID 36879039, PMID 36972467, PMID 36986521, PMID 37083360, PMID 37895905, PMID 38193393, PMID 38320123, PMID 38695960, PMID 38710951
2018 (1)